Category: Cognitive decline

Over 6 million Americans are affected by Alzheimer's disease, a leading cause of cognitive decline. Recent advances have led to FDA approval of new medications for cognitive decline, including Leqembi (lecanemab) and Kisunla (donanemab), marking a new era in treatment by targeting the underlying pathology.

According to a 2017 meta-analysis published in the journal *CNS Drugs*, long-term use of benzodiazepines like Klonopin was associated with statistically significant negative effects across multiple cognitive domains. This robust evidence confirms that chronic use of this medication can indeed impact a person's mental faculties, raising serious questions about whether Klonopin causes cognitive decline and if these effects are reversible.

According to a survey published in *PLOS ONE*, over 57% of long-term benzodiazepine users reported memory loss lasting a year or longer, highlighting a significant and persistent cognitive issue. This raises serious questions about the potential for long-term benzo use to cause lasting memory impairment.